Sector News

Merck to acquire German contract development company AmpTec

January 10, 2021
Life sciences

Merck has announced the acquisition of Germany-based, mRNA contract development and manufacturing organisation (CDMO) AmpTec.

The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.

Merck CEO and executive board chairman Stefan Oschmann said: “The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases.

“By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing, we are able to provide a truly differentiated and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market.”

Merck’s Life Science business sector’s SAFC portfolio includes lipids, which serve as major components for mRNA therapeutics formulation including for Covid-19 vaccines.

The company is partnering with over 50 vaccine manufacturers to aid in Covid-19 vaccine, treatment and service development and production efforts.

Another vital component of mRNA manufacturing is PCR technology. AmpTec utilises a distinguished PCR-based technology for producing mRNA.

As compared to others, PCR-based manufacturing technology has benefits such as homogeneity, purity, activity and flexibility, increased quality, better performance, as well as adaptable capping options to reach specific performance needs.

Apart from its specialisation in mRNA technology, AmpTec has a diagnostics business focused on making customised long RNAs and DNAs for in vitro diagnostics, which will complement existing Merck portfolio.

AmpTec managing directors and founders Guido Krupp and Peter Scheinert said: “AmpTec’s more than 40 employees are thrilled to join Merck and are confident that our PCR-based technology and combined expertise will allow us to offer customers innovative technologies, products and services to help advance life-enhancing therapeutics.”

Financial terms of the deal remain undivulged.

Last November, Merck signed a definitive agreement to acquire all outstanding shares of clinical-stage biopharmaceutical firm OncoImmune through a subsidiary, for an upfront payment of $425m in cash.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend